This ASX healthcare share has jumped 280% in just two days!

Shareholders of this healthcare stock will be smiling long into the weekend.

| More on:
A bearded man holds both arms up diagonally and points with his index fingers to the sky with a thrilled look on his face over these rising Tassal share price

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Dimerix Ltd (ASX: DXB) share price is rising strongly for a second day in a row.

So much so, at one stage today, the ASX healthcare share was up a further 48% to a 52-week high of 23 cents.

When Dimerix's shares reached that level, it meant they were up a mind-boggling 280% in the space of just two days.

The clinical-stage biopharmaceutical company's shares have pulled back a touch since hitting that high, but remain up 25% to 19.5 cents currently.

Why is this ASX healthcare share rocketing?

Investors have been scrambling to buy Dimerix's shares this week after it announced a licensing agreement with Advanz Pharma that could be worth up to ~$230 million.

The agreement is for its phase 3 drug candidate, DMX-200, for the treatment of focal segmental glomerulosclerosis (FSGS) kidney disease.

FSGS is a rare disease that causes kidney scarring and can lead to end-stage kidney disease. DMX-200's trials to date have been very promising and the first analysis outcome from its phase 3 trial is expected in March 2024.

This licensing agreement with Advanz Pharma, which covers DMX-200 in Australia, Canada, Europe, and New Zealand, would clearly be a big deal for the company. With a market capitalisation of approximately $80 million, it could generate revenue almost three times greater than its current valuation.

However, it does have to gain approval from regulators before that happens. It is also worth noting that the ~$230 million deal is predominantly based on unspecified milestones. So, it is unclear what will need to be achieved for the company to receive these funds.

Nevertheless, this is great news for the ASX healthcare share and shareholders will no doubt be eagerly awaiting an update on DMX-200 in March.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

pause in medical asx share price represented by doctor holding hand up in stop motion
Healthcare Shares

ASX 200 healthcare stock up 40% in 6 months halted ahead of major trial results

Neuren Pharmaceuticals will reveal Phase 2 clinical results for its second drug candidate shortly.

Read more »

Shot of a young scientist using a digital tablet while working in a lab.
Healthcare Shares

Can CSL shares deliver market-beating returns for investors?

Is this a good place to invest your hard-earned money? Let's find out.

Read more »

A man in a business suit whose face isn't shown hands over two australian hundred dollar notes from a pile of notes in his other hand to an outstretched hand of another person.
Healthcare Shares

Guess which ASX All Ords insider just bought 50 million shares in their company

Some major insider buying has taken place. What does this mean?

Read more »

Man with a sleep apnoea mask on whilst sleeping.
Broker Notes

ResMed shares higher as company 'turns the GLP threat into an opportunity': Fundie

ResMed is having a great run in 2024 with the share price up 29% already.

Read more »

Male doctor in a lab coat working at laptop looking serious.
Share Fallers

Why this ASX 200 healthcare stock is tumbling 6% today

Inflation pressures are claiming another victim as this healthcare giant lowers its FY24 expectations.

Read more »

Research, collaboration and doctors working digital tablet, analysis and discussion of innovation cancer treatment. Healthcare, teamwork and planning by experts sharing idea and strategy for surgery.
Healthcare Shares

Buy, hold or sell these 3 ASX 200 healthcare shares: Experts

These experts reveal their calls on CSL, Resmed and Sonic Healthcare shares today.

Read more »

Doctor doing a telemedicine using laptop at a medical clinic
Share Gainers

Guess which ASX healthcare stock just exploded 63% on Federal budget funding news!

Investors are bidding up the ASX healthcare stock amid extra funding in the Federal budget.

Read more »

two doctors smile as they sit together at a desk looking at a patient's Xray.
Healthcare Shares

This ASX 200 healthcare stock just hit an all-time high: Is it too late to buy?

The valuation of this high-performer has soared.

Read more »